Literature DB >> 10737275

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

J A Heit1, D N Mohr, M D Silverstein, T M Petterson, W M O'Fallon, L J Melton.   

Abstract

BACKGROUND: The appropriate duration of oral anticoagulation after a first episode of venous thromboembolism (VTE) is uncertain and depends upon VTE recurrence rates.
OBJECTIVE: To estimate VTE recurrence rates and determine predictors of recurrence.
METHODS: Patients in Olmsted County, Minnesota, with a first lifetime deep vein thrombosis or pulmonary embolism diagnosed during the 25-year period from 1966 through 1990 (N = 1,719) were followed forward in time through their complete medical records in the community for first VTE recurrence.
RESULTS: Four hundred four patients developed recurrent VTE during 10,198 person-years of follow-up. The overall (probable/definite) cumulative percentages of VTE recurrence at 7, 30, and 180 days and 1 and 10 years were 1.6% (0.2%), 5.2% (1.4%), 10.1% (4.1%), 12.9% (5.6%), and 30.4% (17.6%), respectively. The risk of recurrence was greatest in the first 6 to 12 months after the initial event but never fell to zero. Independent predictors of first overall VTE recurrence included increasing age and body mass index, neurologic disease with paresis, malignant neoplasm, and neurosurgery during the period from 1966 through 1980. Independent predictors of first probable/definite recurrence included diagnostic certainty of the incident event and neurologic disease in patients with hospital-acquired VTE. Recurrence risk was increased by malignant neoplasm but varied with concomitant chemotherapy, patient age and sex, and study year.
CONCLUSIONS: Venous thromboembolism recurs frequently, especially within the first 6 to 12 months, and continues to recur for at least 10 years after the initial VTE. Patients with VTE with neurologic disease and paresis or with malignant neoplasm are at increased risk for recurrence, while VTE patients with transient or reversible risk factors are at less risk.

Entities:  

Mesh:

Year:  2000        PMID: 10737275     DOI: 10.1001/archinte.160.6.761

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  160 in total

1.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

2.  Invited commentary: Diet and risk of venous thromboembolism--a hard nut to crack.

Authors:  Pamela L Lutsey
Journal:  Am J Epidemiol       Date:  2011-12-15       Impact factor: 4.897

Review 3.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 4.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

5.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Low intensity warfarin anticoagulation is safe and effective as a long-term venous thromboembolism prevention strategy.

Authors:  Samuel Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 7.  The epidemiology of venous thromboembolism in the community.

Authors:  John A Heit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03       Impact factor: 8.311

Review 8.  Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis.

Authors:  Minh Phan; Sonia John; Ana I Casanegra; Suman Rathbun; Aaron Mansfield; Julie A Stoner; Alfonso J Tafur
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 9.  Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.

Authors:  Franco Dammacco; Angelo Vacca; Pasquale Procaccio; Roberto Ria; Ilaria Marech; Vito Racanelli
Journal:  Clin Exp Med       Date:  2013-03-02       Impact factor: 3.984

10.  Venous thromboembolism in the elderly. A community-based perspective.

Authors:  Frederick A Spencer; Joel M Gore; Darleen Lessard; Cathy Emery; Luigi Pacifico; George Reed; Jerry H Gurwitz; Robert J Goldberg
Journal:  Thromb Haemost       Date:  2008-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.